Frager J, Barnet A, Weiss I, Coleman M
J Ment Defic Res. 1985 Sep;29 ( Pt 3):241-6. doi: 10.1111/j.1365-2788.1985.tb00334.x.
Cortical auditory evoked potentials (CAEPs) were recorded at 1 and at 3 years of age in 19 children with Down's syndrome participating in a double blind trial of vitamin B6 and placebo begun in early infancy and continued for 3 years. CAEPs have previously been shown to have abnormally high amplitude in Down's syndrome patients. The CAEPs of the patients in the B6-treated and placebo groups were compared. Only minor effects were found in the CAEPs recorded at 1 year of age. At 3 years of age, however, comparison of the B6-treated group and the placebo group revealed significant differences in both amplitudes and latencies of CAEP components. Peak to peak amplitudes of prominent components were significantly lower in B6-treated patients than in their placebo controls. Amplitude correlated in some cases with whole blood serotonin levels. Latencies for several prominent evoked peaks were significantly longer in B6-treated patients.
对19名患有唐氏综合征的儿童在1岁和3岁时记录了皮质听觉诱发电位（CAEP），这些儿童参与了一项从婴儿早期开始并持续3年的维生素B6和安慰剂双盲试验。此前已表明唐氏综合征患者的CAEP具有异常高的振幅。比较了B6治疗组和安慰剂组患者的CAEP。在1岁时记录的CAEP中仅发现了轻微影响。然而，在3岁时，B6治疗组和安慰剂组的比较显示，CAEP成分的振幅和潜伏期均存在显著差异。B6治疗患者中突出成分的峰峰值振幅明显低于其安慰剂对照。在某些情况下，振幅与全血血清素水平相关。B6治疗患者中几个突出诱发峰的潜伏期明显更长。
